Tag Archives: Flagship Biosciences

February 2024—Flagship Biosciences and Offspring Biosciences announced a strategic partnership to provide a comprehensive suite of preclinical and clinical services. The partnership allows the companies to leverage their combined expertise in preclinical and clinical trial assays to provide their drug development partners an end-to-end solution within North America and Europe.

March 2023—Flagship Biosciences announced a partnership with Genomenon in which Genomenon’s Mastermind knowledge base will provide disease-specific genomic data sets to enrich Flagship’s genomic profiling services. The partnership aims to accelerate biomarker discovery and companion diagnostics development solutions and improve patient stratification for clinical trials and treatment selection.  

August 2020—Flagship Biosciences launched a clinical diagnostics immuno-oncology service, TissueInsight, which provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment, including information on tumor infiltrating lymphocytes and macrophages.

June 2019—Indivumed and Flagship Biosciences have announced a partnership in which the companies will offer a comprehensive set of services combining Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities.

October 2018—Flagship Biosciences announced that its Muscle­Map algorithm that supports therapeutic development for Duchenne muscular dystrophy has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory Medicine.